The Corporate Assembly in Norsk Hydro ASA on Tuesday approved Svein Kåre Sund as new member of Hydro's Board of Directors for a period of 2 years. Sund replaces Ove Ellefsen as one of the Board`s three employee representatives. Billy Fredagsvik and Sten Roar Martinsen was re-elected for a period of 2 years.
After Tuesday's election, the Board of Directors in Hydro consists of chair Dag Mejdell, deputy chair Irene Rummelhoff, Finn Jebsen, Thomas Schulz, Liv Monica Bargem Stubholt, Marianne Wiinholt, and the employee-elected board members Billy Fredagsvik, Sten Roar Martinsen and Svein Kåre Sund.
Investor contact
Contact Stian Hasle
Cellular +47 97736022
E-mail [email protected]
Press contact
Contact Halvor Molland
Cellular +47 92979797
E-mail [email protected]
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 



